![]() Similarly, BFS Molecular focuses on transplant patients by using next-generation sequencing (NGS) to monitor the health of transplanted organs and stem cells over time. CareDx and BFS Molecular Merge for Transplant MonitoringĬareDx, a precision medicine company focused on transplant patients, has acquired BFS Molecular, a posttransplant surveillance company.ĬareDx offers a number of services to transplant patients that include genetic matching solutions, human leukocyte antigen typing technologies, and digital healthcare solutions designed to personalize care from the beginning to the end stages of transplant procedures. The companies have agreed to $24.05 per share for an all-cash deal. Under the terms of the agreement, Roche will receive all outstanding shares of GenMark’s common stock. The acquisition was unanimously approved by the board of directors of Roche and GenMark. ![]() GenMark in return will broaden commercialization of its products through Roche’s worldwide network of consumers. GenMark’s offerings also will complement Roche’s portfolio of COVID-19 diagnostic solutions, as Roche will gain access to GenMark’s Respiratory Pathogen Panels, which identify the most common viral and bacterial organisms associated with upper respiratory infection, including SARS-CoV-2. “Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio to include solutions that can provide lifesaving information quickly to patients and their healthcare providers in the fight against infectious diseases.” “The rapid identification of bloodstream infections and the detection of antimicrobial resistance genes are more essential than ever for hospitals and their patients,” said Thomas Schinecker, CEO of Roche Diagnostics. The ePlex platform is designed to detect multiple pathogens from a single rapid test and a patient sample, allowing clinicians to determine a cause of infection and prescribe treatment within hours. The companies believe that GenMark’s ePlex systems will enhance Roche’s work in managing infectious diseases and antibiotic resistance. Through the acquisition, Roche aims to expand its portfolio of molecular diagnostics with GenMark’s expertise in syndromic testing. Roche and GenMark Diagnostics have entered into a merger agreement in which Roche will fully acquire GenMark for $1.8 billion. Roche Acquires GenMark in $1.8 Billion Deal
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |